Please login to the form below

Not currently logged in

GSK and MaRS launch innovation fund

GlaxoSmithKline and MaRS Innovation have set up a development fund that will support the commercialisation of translational research from 16 academic health science centres, hospitals and universities in Canada

GlaxoSmithKline (GSK) and MaRS Innovation (MI) – an organisation to help create successful global businesses from Canada's science, technology and social innovation - have set up a development fund that will support and fast-track the commercialisation of translational research coming from 16 academic health science centres, hospitals and universities in Canada.

The GSK/MI fund will support projects with strong potential for commercialisation in drug development, diagnostics and healthcare delivery technologies. The partnership will provide access to capitals and opportunities for early engagement with experts to guide and position technologies for successful commercialisation through licensing or start-up company creation.

Paul Lucas, president and chief executive of GSK Canada, said: "Collaborations such as these, where we share knowledge, expertise and resource, provide a highly effective way of progressing and commercialising cutting edge research. We hope that this collaboration will help close the innovation gap in Canada."

MI is a not-for-profit organisation funded through the Canadian government's Networks of Centres of Excellence and contributions from its member institutions.

1st June 2011


COVID-19 Updates and Daily News

Featured jobs


Add my company

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...